Debevoise Advises CD&R in Its Acquisition of R1 at an Enterprise Value of $8.9B
August 02, 2024
August 02, 2024
NEW YORK, Aug. 2 -- Debevoise and Plimpton, a law firm, issued the following news:
Debevoise & Plimpton LLP is advising Clayton, Dubilier & Rice in its acquisition, together with TowerBrook Capital Partners, of R1 RCM Inc. (NASDAQ: RCM) ("R1"), at an enterprise value of $8.9 billion.
R1 is a provider of technology-driven solutions that impact the patient experience and financial performance of healthcare providers.
The Debevoise team is le . . .
Debevoise & Plimpton LLP is advising Clayton, Dubilier & Rice in its acquisition, together with TowerBrook Capital Partners, of R1 RCM Inc. (NASDAQ: RCM) ("R1"), at an enterprise value of $8.9 billion.
R1 is a provider of technology-driven solutions that impact the patient experience and financial performance of healthcare providers.
The Debevoise team is le . . .